Skip to main content

New HRT Guidelines Issued by USPSTF


May 28, 2012 — Menopausal hormone therapy (HRT) reduced risk of fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary incontinence, according to a systematic review of articles published after 2002. Whereas estrogen alone decreased the risk for breast cancer, estrogen plus progestin increased risk for probable dementia and breast cancer. This new review, published online May 29 in the Annals of Internal Medicine, will be used to update the US Preventive Services Task Force recommendations.
"Menopausal hormone therapy to prevent chronic conditions is currently not recommended because of its adverse effects," write Heidi D. Nelson, MD, MPH, from the Oregon Health & Science University in Portland, and colleagues.
"The current indications for use from the U.S. Food and Drug Administration include short-term treatment of menopausal symptoms, such as vasomotor hot flashes or urogenital atrophy, and prevention of osteoporosis."
For the systematic review, Dr. Nelson and colleagues searched MEDLINE for articles published from January 2002 to November 2011, the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews through the third quarter of 2011, Scopus, and bibliographies of retrieved articles. They limited inclusion to studies that were randomized, placebo-controlled trials of menopausal hormone therapy; evaluation of primary prevention of chronic conditions; and English-language publication since 2002.
Data were extracted regarding participants, study design, analysis, follow-up, and findings. Using established criteria, 2 investigators independently rated study quality.
The investigators identified 9 fair-quality trials meeting the inclusion criteria. Most of the findings came from the Women's Health Initiative (WHI), with 11 years of follow-up and collection of data most relevant to postmenopausal American women.
In the WHI, estrogen plus progestin therapy was associated with 46 fewer fractures per 10,000 woman-years. However, women taking HRT had an increased risk for invasive breast cancer (8 more per 10,000 woman-years), stroke (9 more per 10,000 woman-years), deep venous thrombosis (12 more per 10,000 woman-years), pulmonary embolism (9 more per 10,000 woman-years), lung cancer death (5 more per 10,000 woman-years), gallbladder disease (20 more per 10,000 woman-years), dementia (22 more per 10,000 woman-years), and urinary incontinence (872 more per 10,000 woman-years).
The risk for breast cancer was greater in women who previously used oral contraceptives or menopausal estrogen plus progestin therapy, or who were current smokers.
Estrogen-only therapy reduced the risk for several adverse outcomes, including fracture (56 fewer per 10,000 woman-years), invasive breast cancer (8 fewer per 10,000 woman-years), and mortality (2 fewer per 10,000 woman-years). However, the treatment increased risks for stroke (11 more per 10,000 woman-years), deep venous thrombosis (7 more per 10,000 woman-years), gallbladder disease (33 more per 10,000 woman-years), and urinary incontinence (1271 more per 10,000 woman-years).
The investigators could not identify subgroups based on age or comorbid conditions in which outcomes of menopausal HRT were consistently different.
Limitations of this review included those inherent in the trials themselves, such as low adherence, high dropout rate, insufficient power to detect risks for some outcomes, and assessment of few regimens.
"Continuing research is needed on such long-term outcomes as cancer and death to fully understand the implications of hormone therapy," the reviewers conclude.
The Agency for Healthcare Research and Quality funded this study and has financial relationships with some of its authors. Disclosures can be viewed at on the journal's Web site .

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more